Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021
Webcast to be held on Thursday, December 16 at 11:00 a.m. EST
NEW YORK and SAN DIEGO, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, is hosting a virtual R&D Day on December 16, 2021 from 11:00 a.m. to 12:00 p.m. EST. Additional details on the event are summarized below.
Zentalis’ management team along with three Key Opinion Leaders (KOLs) will present preclinical science from multiple programs and clinical updates on ZN-d5, the Company’s oral, selective BCL-2 inhibitor for hematologic malignancies, and ZN-e4, the Company’s oral EGFR inhibitor for non-small cell lung carcinoma.
- Tony Letai, M.D., Ph.D., Professor of Medicine, Hematologic Neoplasia/Malignancies, Dana-Farber Cancer Institute; Professor, Medicine, Harvard Medical School
- Ross Levine, M.D., Chair, Memorial Sloan Kettering Cancer Center
- Kwok Wong, M.D., Ph.D., Anne Murnick Cogan and David H. Cogan Professor of Oncology, Department of Medicine at NYU Grossman School of Medicine; Director, Division of Hematology and Medical Oncology
To register for the event, please visit the Investors page of Zentalis’ website, www.zentalis.com. A live webcast will also be accessible from the Investors page on the day of the event. Afterward, an archived webcast and presentation will be available for replay.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is developing a broad pipeline of potentially best-in-class oncology candidates, all internally discovered, which include ZN-c3, a WEE1 inhibitor for advanced solid tumors, ZN-c5, an oral selective estrogen receptor degrader (SERD) for ER+/HER2- breast cancer, ZN-d5, a BCL-2 inhibitor for hematologic malignancies, and ZN-e4, an EGFR inhibitor for non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c3, ZN-c5 and ZN-d5 to its joint venture, Zentera Therapeutics, to develop and commercialize these candidates in China. Zentalis has operations in both New York and San Diego.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding our product pipeline and our upcoming virtual R&D Day. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to the important factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2021 filed with the U.S. Securities and Exchange Commission (SEC) and our other filings with the SEC. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.